249 related articles for article (PubMed ID: 35960333)
1. CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?
Ganapathy T; Radhakrishnan R; Sakshi S; Martin S
Cancer Immunol Immunother; 2023 Feb; 72(2):277-286. PubMed ID: 35960333
[TBL] [Abstract][Full Text] [Related]
2. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
[TBL] [Abstract][Full Text] [Related]
3. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
4. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
[TBL] [Abstract][Full Text] [Related]
5. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
[TBL] [Abstract][Full Text] [Related]
6. Gamma/delta T cells as cellular vehicles for anti-tumor immunity.
Wang CQ; Lim PY; Tan AH
Front Immunol; 2023; 14():1282758. PubMed ID: 38274800
[TBL] [Abstract][Full Text] [Related]
7. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
8. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
Front Immunol; 2020; 11():1347. PubMed ID: 32714329
[TBL] [Abstract][Full Text] [Related]
9. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
12. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
13. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
Front Immunol; 2019; 10():2717. PubMed ID: 31824502
[TBL] [Abstract][Full Text] [Related]
14. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
15. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
[TBL] [Abstract][Full Text] [Related]
16. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ
Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945
[TBL] [Abstract][Full Text] [Related]
17. [Novel therapy for malignant lymphoma: adoptive immuno-gene therapy using chimeric antigen receptor(CAR)-expressing T lymphocytes].
Ozawa K
Nihon Rinsho; 2014 Mar; 72(3):547-52. PubMed ID: 24724418
[TBL] [Abstract][Full Text] [Related]
18. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
20. A Simple and Robust Single-Step Method for CAR-Vδ1 γδT Cell Expansion and Transduction for Cancer Immunotherapy.
Ferry GM; Agbuduwe C; Forrester M; Dunlop S; Chester K; Fisher J; Anderson J; Barisa M
Front Immunol; 2022; 13():863155. PubMed ID: 35711450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]